French Glendon E. III's Form 4/A amendment
AmendedPulmonx Corp (LUNG) · filed Dec 3, 2021
- Accession no.
- 0001209191-21-067997
- Filed
- Dec 3, 2021
- Trade date
- May 20, 2021
- Filing delay
- 197 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- May 21, 2021
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.05M. It was filed 197 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| French Glendon E. IIICIK 0001805624 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2021 | Common Stock | MOption exerciseAcquired | +10,000 | $2.20 | +$22,000 | 1,259,884 | Direct | |
| May 20, 2021 | Common Stock | SSaleDisposed | −5,059 | $41.01F2 | −$207,469.59 | 1,254,825 | Direct | |
| May 20, 2021 | Common Stock | SSaleDisposed | −19,941 | $42.19F3 | −$841,310.79 | 1,234,884 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2021 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 174,999 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.71 to $41.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.85 to $42.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date.
Remarks
This amendment is filed to correct the inadvertent omission of the option exercise transaction and the amount of securities beneficially owned following the reported transactions in columns 9 and 5 of each of the reported row in Table II and Table I, respectively. The error in columns 9 and 5 also appears in subsequent Forms 4 filed through November 22, 2021.